Slide 1: 2024 Corporate Presentation: Advanced Technology That Makes Water Better
2024 Corporate Presentation Advanced Technology That Makes Water Better — Robert Banks, President and CEO NEPHROS because water matters™
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this management presentation constitute ‘forward-looking statements,” Such stalements include those regarding the efficacy and Intended use of our technologies under development, the timelines and strategy for bringing such producs to market, the avallaill
Slide 3: Overview
NEPHROS Overview Nephros provides leading filtration solutions to a variety of industries including healthcare, hospitality, institutions, government, and manufacturing Nephros water filters support medical and commercial use, with options for contaminants like scale or sediment, and FDA-cleared Cla
Slide 4: Investment Highlights
NEPHROS 4 Investment Highlights + New executive team rationalizing and re-energizing leading water filtration provider + Proprietary technology with muttiple competitive advantages + Growing demand fueled by regulatory tailwinds + ASHRAE 514 - infection control + $1108 - sterile processing + AAMI st
Slide 5: Professional Executive Team
NEPHROS Professional Executive Team ROBERT BANKS President & CEO Robert has a proven track record of delivering value through innovation and aligning the strengths of his organization with customer needs to drive profitable growth. Most recently, he was the Executive Director of Product Management a
Slide 6: Board Of Directors
NEPHROS Board Of Directors —— ROBERT BANKS President & Chief Executive Officer Responsible for leading the organization with 2 clear, set vision, developing 2 strategy to achieve that vision, and then executing that strategy. Robert leads our team to success by inspiring and motivating emaloyees, bu
Slide 7: Water Filtration Business Segments
NEPHROS Water Filtration Business Segments Nephros water filtration business is comprised of two segments: medical water fitration and ‘commercial water filtration We offer a robust line-up of solutions that support an array of installation applications for both water safety and quality 2024 CORPORA
Slide 8: Medical Filtration
NEPHROS Medical Filtration Medical water filtration is our core business, and within this segment are two sub-categories: Infection Control and Dialysis All solutions in this segment are FDA 510(k)-cleared as Class Il medical devices for effective retention of waterborne pathogens FDA 510(k) 2024 CO
Slide 9: Medical Filtration: Superior Technology
NEPHROS 9 MEDICAL FILTRATION Superior Technology Our FDA Class II water filters are capable of effectively retaining bacteria, viruses, and endotoxins with proprietary, hollow-fiber media. This exceptional filtration technology is born from years of service in the field of dialysis, arguably the gol
Slide 10: Infection Control
NEPHROS 1 INFECTION CONTROL == Infection Control —— BENEFITS AND CAPABILITIES © Purify EPA-quality water to be suitable for drinking, surgical handwashing, and medical equipment cleaning © Aid in infection control while supporting facility safety and continuity of operations ) ® Provide effective ba
Slide 11: Infection Control Business Drivers
NEPHROS 2024 CORPORATE PRESENTATION 11 Wao MSY INFECTION CONTROL Infection Control Business Drivers INFLUENCES + CMS, TJC, ASHRAE + ASHRAE 188 and (new) 514 detail water management plan guidance CUSTOMERS + Healthcare facilities, + Government + Manufacturing + Schools + Labs ‘SALE TYPES + Programmat
Slide 12: Dialysis
NEPHROS 2024 CORPORATE PRESENTATION 12 DIALYSIS ———— Dialysis === BENEFITS AND CAPABILITIES ®@ Offer sub-micron purification of water and bicarbonate concentrate following other water treatment equipment, such as reverse osmosis © Ideal for a variety of configurations throughout the dialysis water l
Slide 13: Dialysis Business Drivers
NEPHROS 2024 CORPORATE PRESENTATION MEDICAL FILTRATION [RDYNRESS Dialysis Business Drivers INFLUENCES CUSTOMERS SALE TYPES + ISO and + Dialysis clinics and + Large accounts ANSI/AAMI dialysis wings within (fewer players) (new standard healthcare facilities |, $T108) p New product + OEM partners deve
Slide 14: Commercial Filtration
NEPHROS NEPHRO 2024 CORPORATE PRESENTATION 14 COMMERCIAL FILTRATION Commercial —— BENEFITS AND CAPABILITIES @ High-quality reduction of water contaminants like lead, scale, and sediment @ Improved equipment performance and efficiency @ Reduced machine maintenance © Available in multiple keys and siz
Slide 15: Commercial Business Drivers
NEPHROS MERCIAL FILTRATION Commercial Business Drivers INFLUENCES, CUSTOMERS SALE TYPES +IAPMO, NSF, and Restaurants and + Programmatic ANSI standards quick-service (recurring restaurants (QSR) replacement + Convenience stores ders) + Hospitality + Facilities with cafeterias and/or staff kitchens 20
Slide 16: Looking Ahead
Looking Ahead
Slide 17: Growth Strategy
NEPHROS Growth Strategy + Continue expansion of sales coverage + Expanding sales team to further capitalize national opportunities + Expanding relationship with key distributors to help market coverage + Increase cross selling between products and applications + Continue converting one-time customer
Slide 18: New Developments
NEPHROS 2024 CORPORATE PRESENTATION 18 New Developments PRODUCTS AND SERVICES + Digital tools to enhance Nephros value + Currently beta testing filter tracker to drive reorders and customer behavior + Development of a “digital twin’ to monitor environmental inputs, anticipate usage, and drive strate
Slide 19: Nano- And Microplastics
NEPHROS 19 66 Nano- And Microplastics Because we have the smallest pore size in the Human exposure presents multiple health concerns market...we are the best filter company to address NMPs.” + Nanoplastics penetrate biological barriers + Leaches toxic chemicals + Results: cellular toxicity, inflamma
Slide 20: New Development: Digital Tools
NEPHROS 20 NEW DEVELOPMENT = NEPHROS “We have take Digital Tools Hoste ce Enhanced Customer Experience towards digitizing our with the A launch of a filter ‘You have 5 expired filters tracker.” + Documentation of filter installations + Captures critical data points + Digital tools increase Nephros v
Slide 21: Growing Customer Base Driving Increasing Revenue Momentum
NEPHROS Growing Customer Base Driving Increasing Revenue Momentum Reported Revenue From Continuing Operations Active Customer Sites 4000 CAGR: 17% 1400 500 2500 800 2000 J a 800 1500 1000 = ° ° Qi 2018 > 242023 Qt 2021 > 042023
Slide 22: Nephros, Inc. — Financial Highlights
NEPHROS 22 Nephros, Inc. — Financial Highlights Consolidated 202304 REVENUE 3,254 2,558 14,238 9,975 Gross Margin 62% 59% 5% 4% EBITDA {630} {887} {1,423) (4,043) Adjusted EBITDA 51} {450} (78) (2,364) Operating Income (Loss) (649) (693) (1,593) (4,335) Net Cash Flow From Operations (234) (193) 827
Slide 23: Selected Balance Sheet Information
NEPHROS 23 Nephros Inc. — Selected Balance Sheet Information Assets December 31, 2023 September 30, 2023 December 31, 2022 Current Assets: Cash And Cash Equivalents 4,307 4,822 3,634 ‘Accounts Receivable, Net 1.496 1443, 1.288 Inventory 2.470 2,268 3,153 Other Curent Assets 132 172 188 Total Current
Slide 24: fan ine
NEPHROS 24 fan ine smigsa y 0.660, 030 Siso5 $4.3 MM 10.5 MM Cash Shares o/s 1.8 MM $0 Total equity grants Debt outstanding 2024 CORPORATE PRESENTATION
Slide 25: Key Takeaways
NEPHROS 25 Key Takeaways + New executive team rationalizing and re-energizing leading water filtration provider + Proprietary technology with multiple competitive advantages + Growing demand fueled by regulatory tailwinds + ASHRAE 514 - infection control + $T108 - sterile processing + AAMI standards
Slide 26: Thank You!
Thank You! Investor Relations Contacts: Kirin Smith “ae” Robert Banks President, PCG Advisory 7, | President & CEO, Nephros, Inc. © 16)8238656 © tamt@pogacvisorzcom (201) 345202110 ©) robertbanks@nephros.com
Slide 27: Appendix
NEPHROS Appendix 2024 CORPORATE PRESENTATION, 27
Slide 28: EBITDA And Adjusted EBITDA
NEPHROS We oe | & ‘ . 2024 CORPORATE PRESENTATION ® 28 EBITDA And Adjusted EBITDA EBITDA and Adjusted EBITDA Definitions and Reconcili GAAP Financial Measures EBITDA is calculated by taking net loss calculated in accordance with generally accepted accounting principles ("GAAP") and excluding all int
Slide 29: EBITDA And Adjusted EBITDA Reconciliation
NEPHROS 29 EBITDA And Adjusted EBITDA Reconciliation Q4 2023 23 (unaudited) YTD 2023 {in thousands) Reconciliation Of Net Loss: Net Loss From Continuing Operations. (654) (1,575) Adjustments: Depreciation Of Property And Equipment, 10 39 Amortization Of Other Assets a 175 Interest Expense 1 2 Intere
Slide 30: Corporate Milestones
NEPHROS Corporate Milestones 1997 2024 CORPORATE PRESENTATION | 30 Nephros founded as spin-off from Columbia University research group to develop a new type of dialysis machine that allows existing Hemodialysis (HD) machines to also deliver Hemodiafiltration (HDF) dialysis to patients in the US. IPO
Slide 31: Corporate Milestones
NEPHROS Corporate | 2019 Milestones 2024 CORPORATE PRESENTATION 31 Acquired Aether Water Systems to establish a presence in non-medical fitration for diversification. Also formed Specialty Renal Products (SRP) subsidiary, to re-start the HDF product market. Also started Pathogen Detection Systems gr
Slide 32: because water matters™
NEPHROS because water matters™ nephros.com